Centessa Pharmaceuticals logo

Centessa PharmaceuticalsNASDAQ: CNTA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United Kingdom

IPO:

28 May 2021

Next earnings report:

28 March 2025

Last dividends:

N/A

Next dividends:

N/A
$2.31 B
-2%vs. 3y high
82%vs. sector
-vs. 3y high
-vs. sector
-37%vs. 3y high
79%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 0 min ago
$17.54+$0.80(+4.78%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

CNTA Latest News

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
globenewswire.com12 November 2024 Sentiment: POSITIVE

BOSTON and LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today reported financial results for the third quarter ended September 30, 2024, and provided a business update.

Wake Up to This Biotech Stock That Still Has Big Potential Upside
marketbeat.com28 September 2024 Sentiment: POSITIVE

Centessa Pharmaceuticals NASDAQ: CNTA is a biotechnology stock that has nearly doubled its value so far this year, and its run may not be over. Analysts at Morgan Stanley have just massively raised their price target for the company.

Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
globenewswire.com26 September 2024 Sentiment: POSITIVE

Late-breaking poster presentation of non-human primate (NHP) data support ORX142 as novel drug candidate for the treatment of excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
globenewswire.com12 September 2024 Sentiment: POSITIVE

BOSTON and LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an upsized underwritten public offering of 15,254,237 of American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $14.75 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $225 million, before deducting underwriting discounts and commissions and offering expenses payable by Centessa. All ADSs sold in the offering were offered by Centessa. The offering is expected to close on or about September 16, 2024, subject to customary closing conditions. Centessa has also granted the underwriters a 30-day option to purchase up to an additional 2,288,135 ADSs at the public offering price, less underwriting discounts and commissions.

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
globenewswire.com11 September 2024 Sentiment: POSITIVE

BOSTON and LONDON, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $150 million of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of ADSs offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
globenewswire.com13 August 2024 Sentiment: POSITIVE

BOSTON and LONDON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today reported financial results and business highlights for the second quarter ended June 30, 2024.

Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA)
zacks.com28 May 2024 Sentiment: POSITIVE

Centessa Pharmaceuticals (CNTA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

7 Biotech Stocks Ready to Ride the Sector's Resurgence
InvestorPlace18 March 2024 Sentiment: POSITIVE

Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
GlobeNewsWire09 February 2024 Sentiment: POSITIVE

BOSTON & LONDON, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced that data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia, will be presented during an oral presentation at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in Frankfurt, Germany, today, February 9, 2024. The Company previously shared Part 5 results during a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting. SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) in registrational studies for the treatment for hemophilia B, with or without inhibitors.

Centessa Pharmaceuticals: Clinical Advances And Unique Business Model Highlight Growth Potential
Seeking Alpha05 February 2024 Sentiment: POSITIVE

Centessa Pharmaceuticals: Clinical Advances And Unique Business Model Highlight Growth Potential

What type of business is Centessa Pharmaceuticals?

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

What sector is Centessa Pharmaceuticals in?

Centessa Pharmaceuticals is in the Healthcare sector

What industry is Centessa Pharmaceuticals in?

Centessa Pharmaceuticals is in the Biotechnology industry

What country is Centessa Pharmaceuticals from?

Centessa Pharmaceuticals is headquartered in United Kingdom

When did Centessa Pharmaceuticals go public?

Centessa Pharmaceuticals initial public offering (IPO) was on 28 May 2021

What is Centessa Pharmaceuticals website?

https://www.centessa.com

Is Centessa Pharmaceuticals in the S&P 500?

No, Centessa Pharmaceuticals is not included in the S&P 500 index

Is Centessa Pharmaceuticals in the NASDAQ 100?

No, Centessa Pharmaceuticals is not included in the NASDAQ 100 index

Is Centessa Pharmaceuticals in the Dow Jones?

No, Centessa Pharmaceuticals is not included in the Dow Jones index

When was Centessa Pharmaceuticals the previous earnings report?

No data

When does Centessa Pharmaceuticals earnings report?

The next expected earnings date for Centessa Pharmaceuticals is 28 March 2025